As part of its continuing product development programme, Hart Biologicals is pleased to announce the availability of a new range of platelet aggregation reagents specifically designed for use with whole blood samples using Multiple Electrode Aggregometry (MEA) systems.

MEA is designed to assess platelet function and can be used to diagnose platelet disorders, including Glanzmann Thrombasthenia and can also predict potential bleeding risk and transfusion requirements in cardiac surgery. 

Until now the company has focused its platelet aggregation products for use on systems more closely associated with laboratories. 

However, due to the increase in scope of the use of systems using whole blood as the sample, opportunities for carrying out platelet aggregation studies outside the routine clinical laboratory have created the need for such a specialised range.

Sales Manager Paul Bates said: “In the modern world more and more people are relying on particular types of drug therapy such as Aspirin or Clopidogrel (Plavix®)* to provide ‘protection’ and prevention against the risk of certain coronary and thrombotic events. 

“These agents can also be used in combination usually involving the combination of aspirinand a second anti-clotting medication in dual antiplatelet therapy (DAPT). 

“Most of the time this standard treatment is effective and blood flow is maintained in an anticoagulated state by these agents so that the formation of blood clots is prevented. 

“Conversely there is a certain percentage of patients whereby this protection is not afforded by this standard approach so dose adjustments and even changes in drug therapy have to be made to overcome the problem. 

“Being able to carry out a quick whole blood measurement close to the patient to assess the likely response to therapy enables clinicians to decide quickly and decisively what is the most appropriate route to take for each individual. 

“With the growing number of direct platelet inhibitors becoming available there is likely to be more and more need for patients to be assessed for drug effectiveness before the type or possible combination of agents is selected.”

Initially two products will be available from the company:

  • ASPIRIN MEA Test 3 x 1ml (HB-5613-FG) 
  • COLLAGEN MEA Test 3 x 1ml (HB-5614-FG) 


Both products can be used directly to assess the platelet response to current anti-thrombotic drugs. 

Also available is a custom MEA adaptor vial holder for use with the company’s reagents on MEA systems. 

More information concerning this item can be found HERE.   

Paul added: “We are very pleased with this initiative as it continues the development of products designed for use outside of our traditional area of scope and is in keeping with other near-patient testing interests, such as the Thrombistat MC1WB solution, a system designed to provide cost-effective anticoagulation testing services out in the community

“We pride ourselves in providing innovative and effective tools for use by the modern-day clinical professional and we will continue to direct our product development programme with that aim in mind.”

You can find out more about the Thrombistat MC1WB at www.thrombistat.co.uk

*Plavix®is a registered trademark of sanofi-aventis.